[424B5] Neuphoria Therapeutics Inc. Prospectus Supplement (Debt Securities)
NeuroBo Pharmaceuticals (NEUP) amended its prospectus supplement to update its at-the-market program, allowing sales of up to $15,478,160 of common stock from time to time through H.C. Wainwright & Co. as sales agent under a previously executed Sales Agreement. Sales may be made in transactions deemed an at-the-market offering under Rule 415(a)(4).
The update reflects eligibility under General Instruction I.B.6 of Form S-3, which limits primary sales to no more than one-third of public float in any 12-month period while public float is below $75 million. Public float was $46,434,480, based on 2,321,724 non-affiliate shares at $20.00 as of October 6, 2025. In the past 12 months, the company sold $5,352,879 under I.B.6. Wainwright earns a 3.0% commission on gross proceeds.
NeuroBo Pharmaceuticals (NEUP) ha modificato il suo supplemento al prospetto per aggiornare il suo programma at-the-market, permettendo vendite fino a $15,478,160 di azioni ordinarie di volta in volta attraverso H.C. Wainwright & Co. come agente di vendita ai sensi di un Accordo di vendita precedentemente stipulato. Le vendite possono essere effettuate in transazioni considerate un offering at-the-market ai sensi della Rule 415(a)(4).
L'aggiornamento riflette l'eligibilità ai sensi di General Instruction I.B.6 of Form S-3, che limita le vendite primarie a non più di un terzo della pubblica flottazione in qualsiasi periodo di 12 mesi mentre la flottazione pubblica è inferiore a 75 milioni di dollari. La flottazione pubblica era $46,434,480, basata su 2,321,724 azioni non affiliate a $20.00 al 6 ottobre 2025. Negli ultimi 12 mesi, l'azienda ha venduto $5,352,879 ai sensi di I.B.6. Wainwright guadagna una commissione del 3.0% sul ricavo lordo.
NeuroBo Pharmaceuticals (NEUP) enmendó su suplemento de prospecto para actualizar su programa at-the-market, permitiendo ventas de hasta $15,478,160 de acciones comunes de vez en cuando a través de H.C. Wainwright & Co. como agente de ventas bajo un Acuerdo de Venta previamente ejecutado. Las ventas pueden realizarse en transacciones consideradas una oferta en el mercado bajo la Regla 415(a)(4).
La actualización refleja la elegibilidad bajo General Instruction I.B.6 of Form S-3, que limita las ventas primarias a no más de un tercio de la flotación pública en cualquier periodo de 12 meses mientras la flotación pública está por debajo de 75 millones de dólares. La flotación pública era de $46,434,480, basada en 2,321,724 acciones de no afiliados a $20.00 al 6 de octubre de 2025. En los últimos 12 meses, la empresa vendió $5,352,879 bajo I.B.6. Wainwright obtiene una comisión del 3.0% de los ingresos brutos.
NeuroBo Pharmaceuticals (NEUP)는 앞서 체결된 판매 계약에 따라 H.C. Wainwright & Co.를 판매 대리인으로 하여 시장가 매출 프로그램을 업데이트하기 위해 회사의 의향서 보충서를 수정했습니다. 판매는 $15,478,160의 보통주를 시점으로 매출할 수 있으며, 거래는 Rule 415(a)(4)에 따라 시장가 공모로 간주될 수 있습니다.
업데이트는 Form S-3의 일반 지침 I.B.6에 따라 적합성을 반영하며, 이는 공모 가능한 유동성의 12개월 동안의 기본 매출을 3분의 1 이하로 제한합니다. 공모 유동성은 75백만 달러 미만일 때만 적용됩니다. 공모 유동성은 $46,434,480였고, 2,321,724 비계열 주식이 $20.00로 2025년 10월 6일 기준으로 산정되었습니다. 지난 12개월 동안 회사는 I.B.6에 따라 $5,352,879를 매출했습니다. Wainwright는 총수익의 3.0%의 커미션을 받습니다.
NeuroBo Pharmaceuticals (NEUP) a modifié son supplément de prospectus afin de mettre à jour son programme de vente sur le marché, permettant des ventes allant jusqu'à $15,478,160 d'actions ordinaires de temps à autre par l'intermédiaire de H.C. Wainwright & Co. en tant qu'agent de vente dans le cadre d'un accord de vente préalablement exécuté. Les ventes peuvent être effectuées dans des transactions considérées comme une offre sur le marché en vertu de la règle 415(a)(4).
La mise à jour reflète l'éligibilité sous General Instruction I.B.6 of Form S-3, qui limite les ventes primaires à pas plus d'un tiers du flottant public sur une période de 12 mois tant que le flottant public est inférieur à 75 millions de dollars. Le flottant public était de $46,434,480, basé sur 2,321,724 actions non affiliées à $20,00 au 6 octobre 2025. Au cours des 12 derniers mois, l'entreprise a vendu $5,352,879 sous I.B.6. Wainwright perçoit une commission de 3,0% sur le produit brut.
NeuroBo Pharmaceuticals (NEUP) hat sein Prospekt-Supplement geändert, um sein Marktprogramm zu aktualisieren, das Verkäufe von bis zu $15,478,160 Stammaktien von Zeit zu Zeit durch H.C. Wainwright & Co. als Verkaufsvertreter im Rahmen einer zuvor geschlossenen Verkaufsvereinbarung ermöglicht. Verkäufe können in Transaktionen erfolgen, die unter Regel 415(a)(4) als Market-at-the-Market-Angebot gelten.
Dieses Update spiegelt die Berechtigung gemäß General Instruction I.B.6 of Form S-3 wider, die Primärverkäufe auf nicht mehr als ein Drittel der öffentlichen Free Float in jedem 12-Monats-Zeitraum begrenzt, während das öffentliche Free Float unter 75 Millionen Dollar liegt. Der öffentliche Free Float war $46,434,480, basierend auf 2,321,724 nicht affiliierten Aktien zu $20.00 per 6. Oktober 2025. In den letzten 12 Monaten hat das Unternehmen $5,352,879 unter I.B.6 verkauft. Wainwright erhält eine Provision von 3,0% des Bruttogewinns.
NeuroBo Pharmaceuticals (NEUP) عدلت ملخص نشرتها الاكتتابي لتحديث برنامج السوق، مما يسمح ببيع حتى $15,478,160 من الأسهم العادية من وقت لآخر من خلال H.C. Wainwright & Co. كوكيل مبيعات بموجب اتفاقية بيع منفذة سابقاً. قد تتم البيع في صفقات تُعتبر عرضاً في السوق بموجب القاعدة 415(a)(4).
يعكس التحديث الأهلية بموجب General Instruction I.B.6 of Form S-3، التي تحد من المبيعات الأساسية إلى ما لا يزيد عن ثلث الادفعتة العامة في أي فترة 12 شهراً بينما تبلغ الادفعة العامة أقل من 75 مليون دولار. كانت الادفعة العامة $46,434,480، بناءً على 2,321,724 سهم غير تابعي عند $20.00 اعتباراً من 6 أكتوبر 2025. في آخر 12 شهراً، باعت الشركة $5,352,879 بموجب I.B.6. تحصد Wainwright عمولة قدرها 3.0% من الإيرادات الإجمالية.
NeuroBo Pharmaceuticals (NEUP) 修改了招股说明书补充文件，以更新其市场销售计划，允许通过H.C. Wainwright & Co.作为销售代理，根据先前签署的销售协议不时销售至多$15,478,160的普通股。销售可以在被视为根据Rule 415(a)(4)的市场发行交易中进行。
此次更新反映了基于Form S-3的一般说明I.B.6的资格，该条款在任何12个月内将初级销售限制为不超过公开浮动的三分之一，前提是公开浮动低于7500万美元。公开浮动为$46,434,480，基于截至2025年10月6日的2,321,724非关联股数，股价为$20.00。在过去的12个月里，公司在I.B.6下出售了$5,352,879。Wainwright的毛收入佣金为3.0%。
- None.
- None.
Insights
Administrative ATM capacity update under I.B.6; neutral impact.
NEUP refreshed its at-the-market capacity to sell up to
I.B.6 caps sales at one-third of public float while below
Economics are straightforward: the agent receives a
NeuroBo Pharmaceuticals (NEUP) ha modificato il suo supplemento al prospetto per aggiornare il suo programma at-the-market, permettendo vendite fino a $15,478,160 di azioni ordinarie di volta in volta attraverso H.C. Wainwright & Co. come agente di vendita ai sensi di un Accordo di vendita precedentemente stipulato. Le vendite possono essere effettuate in transazioni considerate un offering at-the-market ai sensi della Rule 415(a)(4).
L'aggiornamento riflette l'eligibilità ai sensi di General Instruction I.B.6 of Form S-3, che limita le vendite primarie a non più di un terzo della pubblica flottazione in qualsiasi periodo di 12 mesi mentre la flottazione pubblica è inferiore a 75 milioni di dollari. La flottazione pubblica era $46,434,480, basata su 2,321,724 azioni non affiliate a $20.00 al 6 ottobre 2025. Negli ultimi 12 mesi, l'azienda ha venduto $5,352,879 ai sensi di I.B.6. Wainwright guadagna una commissione del 3.0% sul ricavo lordo.
NeuroBo Pharmaceuticals (NEUP) enmendó su suplemento de prospecto para actualizar su programa at-the-market, permitiendo ventas de hasta $15,478,160 de acciones comunes de vez en cuando a través de H.C. Wainwright & Co. como agente de ventas bajo un Acuerdo de Venta previamente ejecutado. Las ventas pueden realizarse en transacciones consideradas una oferta en el mercado bajo la Regla 415(a)(4).
La actualización refleja la elegibilidad bajo General Instruction I.B.6 of Form S-3, que limita las ventas primarias a no más de un tercio de la flotación pública en cualquier periodo de 12 meses mientras la flotación pública está por debajo de 75 millones de dólares. La flotación pública era de $46,434,480, basada en 2,321,724 acciones de no afiliados a $20.00 al 6 de octubre de 2025. En los últimos 12 meses, la empresa vendió $5,352,879 bajo I.B.6. Wainwright obtiene una comisión del 3.0% de los ingresos brutos.
NeuroBo Pharmaceuticals (NEUP)는 앞서 체결된 판매 계약에 따라 H.C. Wainwright & Co.를 판매 대리인으로 하여 시장가 매출 프로그램을 업데이트하기 위해 회사의 의향서 보충서를 수정했습니다. 판매는 $15,478,160의 보통주를 시점으로 매출할 수 있으며, 거래는 Rule 415(a)(4)에 따라 시장가 공모로 간주될 수 있습니다.
업데이트는 Form S-3의 일반 지침 I.B.6에 따라 적합성을 반영하며, 이는 공모 가능한 유동성의 12개월 동안의 기본 매출을 3분의 1 이하로 제한합니다. 공모 유동성은 75백만 달러 미만일 때만 적용됩니다. 공모 유동성은 $46,434,480였고, 2,321,724 비계열 주식이 $20.00로 2025년 10월 6일 기준으로 산정되었습니다. 지난 12개월 동안 회사는 I.B.6에 따라 $5,352,879를 매출했습니다. Wainwright는 총수익의 3.0%의 커미션을 받습니다.
NeuroBo Pharmaceuticals (NEUP) a modifié son supplément de prospectus afin de mettre à jour son programme de vente sur le marché, permettant des ventes allant jusqu'à $15,478,160 d'actions ordinaires de temps à autre par l'intermédiaire de H.C. Wainwright & Co. en tant qu'agent de vente dans le cadre d'un accord de vente préalablement exécuté. Les ventes peuvent être effectuées dans des transactions considérées comme une offre sur le marché en vertu de la règle 415(a)(4).
La mise à jour reflète l'éligibilité sous General Instruction I.B.6 of Form S-3, qui limite les ventes primaires à pas plus d'un tiers du flottant public sur une période de 12 mois tant que le flottant public est inférieur à 75 millions de dollars. Le flottant public était de $46,434,480, basé sur 2,321,724 actions non affiliées à $20,00 au 6 octobre 2025. Au cours des 12 derniers mois, l'entreprise a vendu $5,352,879 sous I.B.6. Wainwright perçoit une commission de 3,0% sur le produit brut.
NeuroBo Pharmaceuticals (NEUP) hat sein Prospekt-Supplement geändert, um sein Marktprogramm zu aktualisieren, das Verkäufe von bis zu $15,478,160 Stammaktien von Zeit zu Zeit durch H.C. Wainwright & Co. als Verkaufsvertreter im Rahmen einer zuvor geschlossenen Verkaufsvereinbarung ermöglicht. Verkäufe können in Transaktionen erfolgen, die unter Regel 415(a)(4) als Market-at-the-Market-Angebot gelten.
Dieses Update spiegelt die Berechtigung gemäß General Instruction I.B.6 of Form S-3 wider, die Primärverkäufe auf nicht mehr als ein Drittel der öffentlichen Free Float in jedem 12-Monats-Zeitraum begrenzt, während das öffentliche Free Float unter 75 Millionen Dollar liegt. Der öffentliche Free Float war $46,434,480, basierend auf 2,321,724 nicht affiliierten Aktien zu $20.00 per 6. Oktober 2025. In den letzten 12 Monaten hat das Unternehmen $5,352,879 unter I.B.6 verkauft. Wainwright erhält eine Provision von 3,0% des Bruttogewinns.
Filed pursuant to Rule 424(b)(5)
Registration No. 333-283306
AMENDMENT NO. 5, dated October 20, 2025
to PROSPECTUS SUPPLEMENT dated January 6, 2025
Up to $15,478,160
Common Stock
This Amendment No. 5 to Prospectus Supplement (this “Amendment”) amends and updates our prospectus supplement, dated January 6, 2025, filed with the Securities and Exchange Commission as part of our registration statement on Form S-3, File No. 333-283306 (the “Prospectus Supplement”). This Amendment should be read in conjunction with the Prospectus Supplement and the accompanying prospectus dated January 6, 2025 (the “Prospectus”), each of which are to be delivered with this Amendment, as well as any of our SEC filings which amend, supplement and update this Prospectus Supplement. This Amendment amends and/or updates only those sections of the Prospectus Supplement set forth in this Amendment (other than as automatically updated and amended by our SEC filings incorporated by reference herein); all other sections of the Prospectus Supplement remain unchanged. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus Supplement, and any future amendments or supplements hereto or thereto.
We have entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated November 18, 2024. Under this Sales Agreement, as updated by this Amendment, we may offer and sell common stock having an aggregate offering price of up to $15,478,160 from time to time through Wainwright, acting as sales agent, in accordance with the Sales Agreement, less any amounts previously sold during the past 12 months, as delineated below.
Sales of the common stock, if any, under this prospectus, as amended, may be made by any method permitted that is deemed an “at the market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Wainwright may sell our common stock by any method permitted by law deemed to be an at-the-market offering as defined in Rule 415(a)(4) promulgated under the Securities Act. Wainwright is not required to sell any specific number or dollar amount of securities but will act as our sales agent using commercially reasonable efforts consistent with their normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq, on mutually agreed terms between the Wainwright and us. There are no minimum sale requirements, and there is no arrangement for funds to be received in any escrow, trust or similar arrangement.
We are filing this Amendment to amend the Prospectus Supplement solely to update the amount of shares of common stock we are eligible to sell under General Instruction I.B.6 of Form S-3 and pursuant to the Sales Agreement. The aggregate market value of our common stock held by non-affiliates, or public float, was approximately $46,434,480 based on 2,321,724 non-affiliate shares of common stock outstanding, based on a closing price of $20.00 per share on October 6, 2025, which was the highest closing sale price of our common stock on the Nasdaq Global Market, the principal market for our common equity, within 60 days of the filing date of this registration statement, as amended. In the past 12 calendar months, we have offered and sold an aggregate of $5,352,879 of shares of our common stock pursuant to General Instruction I.B.6 of Form S-3. In no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million.
Wainwright will be entitled to a commission of 3.0% of the gross sales price per share sold under the Sales Agreement. See “Plan of Distribution” beginning on page S-11 of our prospectus supplement, dated January 6, 2025 for additional information regarding the compensation to be paid to Wainwright. In connection with the sale of the common stock on our behalf, Wainwright will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation paid to Wainwright will be deemed to be underwriting compensation. We have also agreed in the Sales Agreement to provide indemnification and contribution to Wainwright with respect to certain liabilities, including liabilities under the Securities Act.
Our common stock is listed on the Nasdaq under the symbol “NEUP.” On October 17, 2025, the last reported sale price of our common stock on the Nasdaq was $15.52 per share.
INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. BEFORE MAKING AN INVESTMENT DECISION, PLEASE READ THE INFORMATION UNDER THE HEADING “RISK FACTORS” BEGINNING ON PAGE S-6 OF THE PROSPECTUS SUPPLEMENT INCLUDED IN THIS REGISTRATION STATEMENT, AND IN THE DOCUMENTS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS SUPPLEMENT.
Neither the Securities and Exchange Commission, any state securities commission, nor any other foreign securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
The date of this Amendment No. 5 to prospectus supplement is October 20, 2025.
FAQ
What is NEUP offering under this amendment to its ATM program?
Which rule and form limit NEUP’s sales capacity in this ATM?
What is NEUP’s public float used for the I.B.6 calculation?
How much has NEUP sold under I.B.6 in the past 12 months?
What commission will H.C. Wainwright receive on ATM sales?
Is NEUP’s ATM considered an at-the-market offering under SEC rules?
Where is NEUP listed and what was the last reported price mentioned?
